Johns Hopkins mKRAS Vaccine Trial Strengthens The Case For Elicio's ELI-002
A Hopkins mKRAS vaccine trial shows KRAS peptides generate durable T cell immunity correlating with survival, consistent with Elicio's AMPLIFY-201.
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results - Nature Medicine
nature.comIn the final analysis of a phase 1 trial evaluating a lymph node-targeting mutant KRAS peptide vaccine combined with CpG in the adjuvant setting for patients with KRAS mutant pancreatic or colorectal cancer, median relapse-free survival and overall survival were not reached for patients with robust antigen-specific T cell responses, and these responses were durable with evidence of antigen spreading.
Monte Carlo Simulation Of Elicio's Phase II AMPLIFY-7P Study Favors Vaccine Efficacy
Monte Carlo simulation maps AMPLIFY-7P's readout delay onto control-arm survival and vaccine HR. Efficacy scenarios fit 2-3x better.
Elicio’s Therapeutic Vaccine For Pancreatic Cancer: A Revolution Hidden In Plain Sight?
Elicio's mKRAS vaccine achieved 84% T-cell response in pancreatic cancer Phase 1. Phase 2 readout in H1 2026 could redefine adjuvant therapy.
Elicio’s Therapeutic Vaccine For Pancreatic Cancer: A Revolution Hidden In Plain Sight?
Elicio Therapeutics is developing an off-the-shelf therapeutic mKRAS vaccine for pancreatic cancer. Phase 1 showed 84% T-cell response correlating with prolonged survival. Phase 2 data expected in H1 2026 will determine whether this approach can transform adjuvant therapy.
Monte Carlo Simulation Of Elicio's Phase II AMPLIFY-7P Study Favors Vaccine Efficacy
The readout of AMPLIFY-7P for ELI-002 7P in pancreatic cancer was expected by late 2025. Fewer events than projected pushed it to H1 2026. Monte Carlo simulation maps this delay onto control-arm survival and hazard ratio, with efficacy scenarios fitting 2–3× better.
Johns Hopkins mKRAS Vaccine Trial Strengthens the Case for Elicio's ELI-002
A Johns Hopkins Phase 1 trial of a pooled mKRAS vaccine with dual checkpoint blockade strengthens the case that mKRAS peptides generate durable, cross-reactive T cell immunity correlating with disease-free survival in resected pancreatic cancer, consistent with Elicio's AMPLIFY-201 data.
Two Delayed Cancer Vaccine Readouts: Why I Am More Optimistic About AMPLIFY-7P Than REGAL
AMPLIFY-7P and REGAL both face delayed readouts as events accumulate slower than projected. A comparison of trial design, mechanistic evidence, and immune correlates, and why my conviction behind ELI-002 in PDAC and GPS in CR2 AML is not equal.